drug
dextroamphetamine ER
Marketedupdated 3mo agoby Noven Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugdextroamphetamine153 co-mentions · 69 sources
- tagApproval118 co-mentions · 54 sources
- drugDYANAVEL XR98 co-mentions · 14 sources
- drugamfetamine ER-ODT98 co-mentions · 14 sources
- drugDYANAVEL XR 2098 co-mentions · 14 sources
- drugdextroamphetamine sulfate ER93 co-mentions · 63 sources
- drugDEXTROAMPHETAMINE SULFATE93 co-mentions · 63 sources
- tagSmall Molecule49 co-mentions · 49 sources
all catalysts(0)
nothing on the calendar yet
Trials studying dextroamphetamine ER
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 24, 2033
~7.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Jan 6, 2042formulationUS 11559501
- Jan 6, 2042formulationUS 11559501
- Jan 6, 2042formulationUS 11559501
- Jan 6, 2042formulationUS 11559501
- Oct 24, 2033formulationUS 9456993
- Oct 24, 2033formulationUS 9456993
- Oct 24, 2033formulationUS 9456993
- Oct 24, 2033formulationUS 9456993
- Oct 24, 2033formulationUS 9474722
- Oct 24, 2033formulationUS 9474722
- Oct 24, 2033formulationUS 9474722
- Oct 24, 2033formulationUS 9474722
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that